BACKGROUND:MicroRNAs(MiRNA) are a novel class of non-coding RNAs involved in the regulation of gene expression post-transcriptionally by cleavage or translational repression of their specific target miRNAs.Numerous st...BACKGROUND:MicroRNAs(MiRNA) are a novel class of non-coding RNAs involved in the regulation of gene expression post-transcriptionally by cleavage or translational repression of their specific target miRNAs.Numerous studies have demonstrated that circulating miRNAs are stable and abundant in blood and aberrantly expressed under pathological conditions,including cardiovascular diseases.The implications of circulating miRNAs in acute myocardial infarction have recently been recognized.This review will highlight the potential role of miRNA as a novel class of biomarkers in acute myocardial infarction.METHODS:This systemic review is based on our own work and other related reports.RESULTS:During diseases circulating miRNAs are derived from not only circulating blood cells but also other tissues affected by ongoing diseases.These disease-related miRNAs in the blood can serve as potential biomarkers.CONCLUSION:The circulating miRNAs can be used as novel biomarkers potentially offering more sensitive and specific tests than those currently available for diagnosis of acute myocardial infarction.展开更多
随着白内障手术步入了微创精准的屈光时代,对于围手术期感染控制提出了更高的要求。近年来,无滴眼液的白内障手术被提出并逐步应用于临床,其是基于白内障手术中联合不同局部注药形式,将抗生素及类固醇等药物通过即时或缓释等方式应用于...随着白内障手术步入了微创精准的屈光时代,对于围手术期感染控制提出了更高的要求。近年来,无滴眼液的白内障手术被提出并逐步应用于临床,其是基于白内障手术中联合不同局部注药形式,将抗生素及类固醇等药物通过即时或缓释等方式应用于术眼,使患者在整个围手术期均不需使用滴眼液。在达到术后抗炎、抗感染目的的同时,也能减少患者、患者家属及医生的负担。本文对无滴眼液的白内障手术的概念、联合用药方式、包括联合前房注射抗生素、曲安奈德与莫西沙星的混合注射剂(triamcinolone acetonide and moxifloxacin hydrochloride,TriMoxi)和曲安奈德、莫西沙星与万古霉素的混合注射剂(triamcinolone-moxifloxacin and vancomycin,TriMoxiVanc)玻璃体腔注射、联合地塞米松泪小点塞植入、持续或缓释药物传递机制等、以及其有效性及安全性等内容进行综述,以期为白内障术后感染预防提供新的思路与方向。展开更多
目的探讨骨质疏松性椎体压缩骨折分别采用传统保守疗法以及PKP微创手术治疗的成本-效果比(C/E),为此类患者治疗方案的选择提供参考依据。方法选择2013-12-2015-03期间收治的110例OVCF住院患者,依据患者的治疗方案选择情况,分为PKP微创...目的探讨骨质疏松性椎体压缩骨折分别采用传统保守疗法以及PKP微创手术治疗的成本-效果比(C/E),为此类患者治疗方案的选择提供参考依据。方法选择2013-12-2015-03期间收治的110例OVCF住院患者,依据患者的治疗方案选择情况,分为PKP微创手术组(n=72)与保守治疗组(n=38)。两组患者治疗后,均随访1年以上,采用VAS与ADL评分对治疗前和出院当天、治疗后3、6个月和1年后的疗效进行评估,并统计其治疗费用(包括住院费用及门诊随访费用),进行成本-效果评价。结果 (1)两组治疗后各时间点,微创PKP手术组的VAS和ADL评分均显著低于保守组(P<0.05);(2)若以"完全正常"为疗效的追求目的,PKP微创组的C/E值仅为909.5,明显低于保守组的2142.0;但若以"功能改善"为疗效的追求目的,PKP微创组的C/E值为374.8,则明显高于保守组的178.3;出院后,PKP微创组的C/E值明显低于保守组(2.65 VS 5.80)。结论在综合考虑疗效、成本-效果、占用医疗资源等因素的前提下,如果以追求更可靠的疗效为前提,可选择PKP微创术式为主的治疗方案;若仅以功能改善为目的,在患者骨折情况允许的条件下,传统保守治疗可降低患者的经济费用负担,但后续费用较高。展开更多
基金supported grants from the National Natural Science Foundation of China(81000076)Priority Academic Program Development of Jiangsu Higher Education Institutions(JX10231081)
文摘BACKGROUND:MicroRNAs(MiRNA) are a novel class of non-coding RNAs involved in the regulation of gene expression post-transcriptionally by cleavage or translational repression of their specific target miRNAs.Numerous studies have demonstrated that circulating miRNAs are stable and abundant in blood and aberrantly expressed under pathological conditions,including cardiovascular diseases.The implications of circulating miRNAs in acute myocardial infarction have recently been recognized.This review will highlight the potential role of miRNA as a novel class of biomarkers in acute myocardial infarction.METHODS:This systemic review is based on our own work and other related reports.RESULTS:During diseases circulating miRNAs are derived from not only circulating blood cells but also other tissues affected by ongoing diseases.These disease-related miRNAs in the blood can serve as potential biomarkers.CONCLUSION:The circulating miRNAs can be used as novel biomarkers potentially offering more sensitive and specific tests than those currently available for diagnosis of acute myocardial infarction.
文摘随着白内障手术步入了微创精准的屈光时代,对于围手术期感染控制提出了更高的要求。近年来,无滴眼液的白内障手术被提出并逐步应用于临床,其是基于白内障手术中联合不同局部注药形式,将抗生素及类固醇等药物通过即时或缓释等方式应用于术眼,使患者在整个围手术期均不需使用滴眼液。在达到术后抗炎、抗感染目的的同时,也能减少患者、患者家属及医生的负担。本文对无滴眼液的白内障手术的概念、联合用药方式、包括联合前房注射抗生素、曲安奈德与莫西沙星的混合注射剂(triamcinolone acetonide and moxifloxacin hydrochloride,TriMoxi)和曲安奈德、莫西沙星与万古霉素的混合注射剂(triamcinolone-moxifloxacin and vancomycin,TriMoxiVanc)玻璃体腔注射、联合地塞米松泪小点塞植入、持续或缓释药物传递机制等、以及其有效性及安全性等内容进行综述,以期为白内障术后感染预防提供新的思路与方向。
文摘目的探讨骨质疏松性椎体压缩骨折分别采用传统保守疗法以及PKP微创手术治疗的成本-效果比(C/E),为此类患者治疗方案的选择提供参考依据。方法选择2013-12-2015-03期间收治的110例OVCF住院患者,依据患者的治疗方案选择情况,分为PKP微创手术组(n=72)与保守治疗组(n=38)。两组患者治疗后,均随访1年以上,采用VAS与ADL评分对治疗前和出院当天、治疗后3、6个月和1年后的疗效进行评估,并统计其治疗费用(包括住院费用及门诊随访费用),进行成本-效果评价。结果 (1)两组治疗后各时间点,微创PKP手术组的VAS和ADL评分均显著低于保守组(P<0.05);(2)若以"完全正常"为疗效的追求目的,PKP微创组的C/E值仅为909.5,明显低于保守组的2142.0;但若以"功能改善"为疗效的追求目的,PKP微创组的C/E值为374.8,则明显高于保守组的178.3;出院后,PKP微创组的C/E值明显低于保守组(2.65 VS 5.80)。结论在综合考虑疗效、成本-效果、占用医疗资源等因素的前提下,如果以追求更可靠的疗效为前提,可选择PKP微创术式为主的治疗方案;若仅以功能改善为目的,在患者骨折情况允许的条件下,传统保守治疗可降低患者的经济费用负担,但后续费用较高。
